KIT and gastrointestinal stromal tumor: Overall, these results primarily demonstrate the potential of SHP2 inhibition as a promising therapeutic strategy to enhance the efficacy of imatinib in KIT‐mutant GIST, particularly in cases with resistance caused by secondary KIT mutations.